Suppr超能文献

2,2'-联吡啶-6-碳硫酰胺及其亚铁配合物:它们与核糖核苷酸还原酶R2亚基抑制相关的体外抗肿瘤活性

2,2'-Bipyridyl-6-carbothioamide and its ferrous complex: their in vitro antitumoral activity related to the inhibition of ribonucleotide reductase R2 subunit.

作者信息

Nocentini G, Federici F, Franchetti P, Barzi A

机构信息

Institute of Medical Pharmacology, University of Perugia, Italy.

出版信息

Cancer Res. 1993 Jan 1;53(1):19-26.

PMID:8416745
Abstract

2,2'-Bipyridyl-6-carbothioamide (BPYTA), a synthetic compound with antitumoral activity, is characterized by chelating properties because of the N*-N*-S* tridentate ligand system and is therefore comparable to alpha-(N)-heterocyclic carboxaldehyde thiosemicarbazones which are potent inhibitors of ribonucleotide reductase (RR). Electron paramagnetic resonance studies on the small subunit of mouse recombinant RR (R2) demonstrated that BPYTA can destroy the R2 tyrosyl radical only if Fe(II) is present (73% destruction at 50 microM, after 20 min of contact). The R2 inhibition was reversible and time dependent. Studies on tumoral lines confirmed that the main cell target of BPYTA is RR and demonstrated that the iron-complexed form compared to the nonchelated form has some difficulty in crossing the cell membrane. Spectrophotometric and electron paramagnetic resonance studies clearly indicated that BPYTA chelates iron only when this is reduced and that the BPYTA-Fe(II) complex is stable in the presence of oxygen. From reported results we conclude that BPYTA is a powerful RR inhibitor (R2 subunit) which has a different mechanism of action from that of Desferal. It has some properties in common with alpha-(N)-heterocyclic carboxaldehyde thiosemicarbazones, but they are not identical. It would be interesting to do further studies on the BPYTA mechanism of action and evaluate the in vivo antitumoral activity of the preformed complex.

摘要

2,2'-联吡啶-6-甲硫酰胺(BPYTA)是一种具有抗肿瘤活性的合成化合物,因其N*-N*-S*三齿配体系统而具有螯合特性,因此可与α-(N)-杂环羧醛硫代半卡巴腙相媲美,后者是核糖核苷酸还原酶(RR)的有效抑制剂。对小鼠重组RR(R2)小亚基的电子顺磁共振研究表明,只有在存在Fe(II)的情况下,BPYTA才能破坏R2酪氨酰自由基(接触20分钟后,50 microM时破坏率为73%)。R2抑制是可逆的且与时间相关。对肿瘤细胞系的研究证实,BPYTA的主要细胞靶点是RR,并表明与非螯合形式相比,铁络合形式在穿过细胞膜方面存在一些困难。分光光度法和电子顺磁共振研究清楚地表明,BPYTA仅在铁被还原时螯合铁,并且BPYTA-Fe(II)络合物在有氧存在下是稳定的。根据报道的结果,我们得出结论,BPYTA是一种强大的RR抑制剂(R2亚基),其作用机制与去铁胺不同。它与α-(N)-杂环羧醛硫代半卡巴腙有一些共同特性,但并不完全相同。进一步研究BPYTA的作用机制并评估预制络合物的体内抗肿瘤活性将是很有意思的。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验